US20220023098A1 - Methods of transverse placement in elt - Google Patents
Methods of transverse placement in elt Download PDFInfo
- Publication number
- US20220023098A1 US20220023098A1 US17/363,726 US202117363726A US2022023098A1 US 20220023098 A1 US20220023098 A1 US 20220023098A1 US 202117363726 A US202117363726 A US 202117363726A US 2022023098 A1 US2022023098 A1 US 2022023098A1
- Authority
- US
- United States
- Prior art keywords
- eye
- probe
- schlemm
- canal
- trabecular meshwork
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 34
- 239000000523 sample Substances 0.000 claims abstract description 75
- 210000001585 trabecular meshwork Anatomy 0.000 claims abstract description 55
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 26
- 210000001742 aqueous humor Anatomy 0.000 claims abstract description 18
- 239000012530 fluid Substances 0.000 claims abstract description 15
- 239000000835 fiber Substances 0.000 claims description 43
- 239000013307 optical fiber Substances 0.000 claims description 11
- 229910052751 metal Inorganic materials 0.000 claims description 5
- 239000002184 metal Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 238000005286 illumination Methods 0.000 claims description 3
- HGCGQDMQKGRJNO-UHFFFAOYSA-N xenon monochloride Chemical compound [Xe]Cl HGCGQDMQKGRJNO-UHFFFAOYSA-N 0.000 claims description 3
- 210000002159 anterior chamber Anatomy 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 230000004410 intraocular pressure Effects 0.000 abstract description 5
- 210000001519 tissue Anatomy 0.000 description 12
- 238000011282 treatment Methods 0.000 description 9
- 210000000695 crystalline len Anatomy 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 5
- 238000013532 laser treatment Methods 0.000 description 5
- 230000002980 postoperative effect Effects 0.000 description 5
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 4
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 229960003150 bupivacaine Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000004406 elevated intraocular pressure Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 210000003786 sclera Anatomy 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 230000003685 thermal hair damage Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000020564 Eye injury Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000153 Povidone-iodine Polymers 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 235000020457 energy shots Nutrition 0.000 description 1
- 231100000040 eye damage Toxicity 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229960001621 povidone-iodine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000002691 topical anesthesia Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F9/00802—Methods or devices for eye surgery using laser for photoablation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00861—Methods or devices for eye surgery using laser adapted for treatment at a particular location
- A61F2009/00868—Ciliary muscles or trabecular meshwork
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/008—Methods or devices for eye surgery using laser
- A61F2009/00885—Methods or devices for eye surgery using laser for treating a particular disease
- A61F2009/00891—Glaucoma
Definitions
- the invention relates generally to excimer laser trabeculostomy (ELT) procedures and fiber probe placement during the procedure.
- ELT excimer laser trabeculostomy
- a leading cause of irreversible blindness is glaucoma.
- fluid flows freely through the anterior chamber of the eye and exits through a drainage system that includes the trabecular meshwork and Schlemm's canal.
- a blockage in the trabecular meshwork or Schlemm's canal prevents the fluid from draining and results in increased pressure in the eye. If left untreated, the increased pressure in the eye damages the optic nerve, leading to gradual vision loss and eventual blindness.
- Traditional methods of treating glaucoma include pharmaceutical treatments, laser treatments, surgical treatments, or combinations thereof to lower pressure in the eye.
- Pharmaceutical treatments such as medicated drops, and laser treatments, such as selective laser trabeculoplasty (SLT), often are not effective in treating advanced stages of glaucoma.
- Invasive surgical treatments such as placement of implants or drainage stents, are used to treat advanced stages of glaucoma.
- the invasive surgical treatments have drawbacks and require great precision to avoid dislodgement of the implant. For example, if a stent is not placed properly on the first attempt, the stent may be difficult to place at all.
- the invention provides treatment of glaucoma using excimer laser trabeculostomy (ELT).
- ELT excimer laser trabeculostomy
- a laser probe is positioned transverse to the Schlemm's canal to create perforations the trabecular meshwork and/or Schlemm's canal.
- By permanently perforating Schlemm's canal and/or the trabecular meshwork built-up fluid in the anterior chamber of the eye is immediately allowed to drain.
- Arrangement of the laser probe at a position transverse to Schlemm's canal provides optimum results by providing a greater amount of surface area for photoablation by the laser.
- each laser shot provides photoablation of a greater amount of surface area, resulting in a greater perforation from fewer laser shots.
- the obstruction of fluid outflow at the trabecular meshwork and inner wall of Schlemm's canal is the primary cause of elevated intraocular pressure (TOP).
- TOP intraocular pressure
- the invention uses an excimer laser to perforate the trabecular meshwork and/or Schlemm's canal to create an internal outflow channel, increasing drainage of the fluid known as aqueous humor from the anterior chamber of the eye. The perforations also increase flow of aqueous humor and reduce pressure in the eye.
- Methods of the invention use ELT to reestablish outflow of fluid from the anterior chamber of the eye without inciting a healing response at the target tissue.
- ELT converts trabecular meshwork tissue into gas by photoablation. Ablation with excimer lasers causes almost no thermal damage, thereby minimizing inflammation and formation of scar tissue. Unlike argon and selective laser trabeculoplasty procedures, ELT precisely excises tissue without causing thermal injury or scarring the surrounding tissue. Moreover, other lasers, such as ruby and argon lasers, cannot achieve a permanent perforation of the trabecular meshwork because of inflammatory and healing responses. Due to the lack of inflammation and scar tissue formation, methods of the invention require less recovery time than traditional laser treatments or surgical treatments, such as placement of implants.
- a physician guides a delivery tip of a fiber probe through a corneal incision in the eye and towards the trabecular meshwork.
- methods of the invention comprise administering anesthesia to the subject before making the incision and inserting the probe.
- the incision has a length of about 1 ⁇ 8 inch or smaller.
- the delivery tip is guided by the physician to a position transverse to the Schlemm's canal.
- the physician uses a light source such as a Gonio lens, endoscope, or other illumination source to aid in positioning the delivery tip.
- the light source aids the physician in verifying the effectiveness of the laser treatment by visualizing drainage of the aqueous humor and bloody reflux emitted during the treatment.
- the physician delivers a series of shots of laser energy to the trabecular meshwork.
- energy from the laser is delivered to a greater amount of surface area than if the fiber probe was placed in a parallel or perpendicular position to the Schlemm's canal.
- arrangement of the delivery tip at a position transverse to the Schlemm's canal achieves optimal photoablation and perforation formation in the meshwork and/or Schlemm's canal.
- the creation of a plurality of perforations in leads to immediate drainage of aqueous humor from the anterior chamber of the eye.
- ELT treatment creates long-term openings that connect the anterior chamber of the eye directly to Schlemm's canal using an excimer laser.
- Some embodiments of the invention use a 308-nm xenon-chloride ultraviolet excimer laser, which causes minimal thermal damage compared with visible or infrared lasers.
- the excimer laser is an encapsulated xenon chloride (XeCl) excimer laser such as the EX TRA LASER manufactured by MLase AG.
- XeCl encapsulated xenon chloride
- an optical fiber is used to deliver the energy from the excimer laser.
- the delivery tip of the fiber probe comprises the optical fiber jacketed in metal, such as stainless steel.
- the delivery tip is beveled (e.g., at 0°, 15°, 30°, and 45° with respect to the tip).
- the fiber probe comprises an optical fiber suitable for UV light that is embedded into a handheld laser applicator.
- a FIDO LASER APPLICATOR manufactured by MLase AG may be used as the fiber probe.
- ELT perforations each having a diameter of about 200 ⁇ m, are lasered into the trabecular meshwork and/or Schlemm's canal.
- stents and implants have smaller individual diameters that are between about 80 ⁇ m to about 120 ⁇ m.
- about 10 shots from an excimer laser source are applied to each eye.
- greater than about 10 shots are applied to each eye. Because ELT is a non-thermal procedure, tissue reactions in the trabecular meshwork are not shown or activated post-operatively.
- FIG. 1 is a flowchart of an embodiment of methods of the invention.
- FIG. 2 is a schematic sectional view of an embodiment of the invention in an eye.
- FIG. 3 shows the schematic section view of an eye with a light source aid.
- FIG. 4 is an enlarged schematic sectional view of an embodiment of the invention.
- FIG. 5 shows an embodiment of systems of the invention.
- FIG. 6 shows an embodiment of an ELT system.
- FIG. 7 shows a capped embodiment of a fiber probe.
- FIG. 8 shows an embodiment of a fiber probe.
- FIG. 9 shows a cross-sectional view of a fiber probe along line A-A of FIG. 8 .
- FIG. 10 shows a cross-sectional view of a fiber probe along line B-B of FIG. 8 .
- Glaucoma patients suffer from increased intraocular pressure due to a blockage of fluid outflow from the eye.
- the invention uses an excimer laser to shoot perforations in the Schlemm's canal and/or trabecular meshwork of the eye.
- ELT treats open-angle glaucoma at the site of occurrence by increasing the permeability of the trabecular meshwork.
- the laser creates a direct connection between the front chamber of the eye and the Schlemm's canal by using a fiber probe in physical contact with the trabecular meshwork.
- Methods of the invention include inserting a probe into an eye of a subject having glaucoma, adjusting placement of the probe to a position transverse to Schlemm's canal in the eye, and applying a plurality of shots from an excimer laser source while the probe is in the transverse position, thereby treating glaucoma by creating a plurality of perforations in Schlemm's canal and/or the trabecular meshwork.
- a laser probe at a position transverse to Schlemm's canal, energy from the laser is delivered to a greater amount of surface area than if the laser was arranged in a parallel or perpendicular position to Schlemm's canal, resulting in optimal formation or perforations.
- the perforations allow immediate drainage of fluid from the anterior chamber of the eye.
- the perforations also allow for increased flow of aqueous humor in the eye and reduced intraocular pressure.
- FIG. 1 shows a flowchart of an embodiment 100 of methods of the invention.
- Methods of the invention are directed to treating a patient having glaucoma with ELT.
- energy shots from the excimer laser are delivered by a fiber probe at a position transverse to the Schlemm's canal.
- methods include 110 pre-operative analysis, such as diagnosis of the eye condition and inspection and/or visualization of the anterior chamber of the eye to aid in placement of the laser probe.
- excimer laser trabeculostomy ELT is used to treat glaucoma.
- the method includes 120 administering anesthesia to the patient.
- Topical anesthesia is commonly employed, typically by the instillation of a local anesthetic such as tetracaine or lidocaine.
- a local anesthetic such as tetracaine or lidocaine.
- Lidocaine and/or a longer-acting bupivacaine anesthetic may be injected into the area surrounding (peribulbar block) or behind (retrobulbar block) the eye muscle cone to more fully immobilize the extraocular muscles and minimize pain sensation.
- a facial nerve block may be performed using lidocaine and bupivacaine to reduce lid squeezing.
- general anesthesia is administered with cardiovascular monitoring.
- a physician 130 makes a small incision on the eye of the patient. Before the ELT procedure is performed, a small incision is made in the cornea of the eye to allow introduction of the fiber probe. Typically, the incision is about 1 ⁇ 8 inch or smaller.
- a physician guides the delivery tip of the fiber probe through the corneal incision in the eye and towards the trabecular meshwork.
- the delivery tip is 140 guided by the physician to a position transverse to the Schlemm's canal.
- a Gonio lens, endoscope, and/or illumination source may be used by the physician to aid in positioning the delivery tip.
- arrangement of the delivery tip at a position transverse to the Schlemm's canal achieves optimal photoablation and formation of perforations in the meshwork and/or Schlemm's canal.
- the orientation and positioning of the delivery tip is critical when creating perforations in the tissue, as achieving transverse placement of perforations in the meshwork relative to Schlemm's canal provides optimal drainage.
- the physician 150 applies ELT treatment to the patient by delivering a series of shots of laser energy to the trabecular meshwork and Schlemm's canal.
- the physician applies pulsed photoablative energy.
- a physician creates about 10 ELT sites in an eye of the patient. In some examples, the physician creates greater than about 10 ELT sites per eye of the patient.
- a small amount of bloody reflux from Schlemm's canal confirms each opening.
- the fiber probe is removed from the eye. The IOP decreases immediately after administering the ELT procedure.
- a physician 160 closes the incision.
- a physician uses sutures to close the incision.
- Some physicians place a suture in the incision and other physicians reserve a suture for instances involving persistent leakage.
- Methods of the invention include 170 analyzing post-operative results and 180 reporting results and/or scheduling a post-operative follow-up appointment with the patient after surgery.
- the physician's analysis may include observing a small amount of bloody reflux from Schlemm's canal to confirm each opening. By observing the bloody reflux and drainage of aqueous humor, the physician is able to immediately verify the effectiveness of the laser treatment.
- the physician may report the results to the patient, prescribe post-operative medication, such as topical antibiotics and steroid drops, and schedule any follow-up post-operative visits with the patient. Topical antibiotics and steroid drops are typically prescribed and used by the patient for 1 to 2 weeks post-operatively.
- FIG. 2 is schematic sectional view of an eye 2100 illustrating the interior anatomical structure.
- FIG. 3 shows the schematic section view of an eye 2100 with a light source 2190 , such as a Gonio lens, endoscope, or other light source.
- FIG. 4 is an enlarged schematic sectional view of the eye.
- the outer layer, or sclera, 2130 serves as a supporting framework for the eye, and the front of the outer layer 2130 includes a cornea 2125 , a transparent tissue that enables light to enter the eye.
- An anterior chamber 2135 is located between the cornea 2125 and a crystalline lens 2110 , and a posterior chamber is located behind the lens 2110 .
- the anterior chamber 2135 contains a constantly flowing clear fluid called aqueous humor.
- an iris 2120 encircles the outer perimeter of the lens 2110 and includes a pupil at its center, which controls the amount of light passing through the lens 2110 .
- the eye further includes a trabecular meshwork 2140 , which is a narrow band of spongy tissue that encircles the iris 2120 within the eye.
- the trabecular meshwork has a variable shape and is microscopic in size. It is of a triangular cross-section and of varying thickness in the range of about 100 microns to about 200 microns. It is made up of different fibrous layers having micron-sized pores forming fluid pathways for the egress of aqueous humor.
- the trabecular meshwork 2140 has been measured to a thickness of about 100 microns at its anterior edge, known as Schwalbe's line, which is at the approximate juncture of the cornea and sclera.
- the trabecular meshwork widens to about 200 microns at its base where it and iris 2120 attach to the scleral spur.
- the passageways through the pores in trabecular meshwork 2140 lead through very thin, porous tissue called the juxtacanalicular trabecular meshwork that abuts the interior side of a structure called Schlemm's canal 2150 .
- Schlemm's canal 2150 is filled with a mixture of aqueous humor and blood components and branches off into collector channels which drain the aqueous humor into the venous system.
- any obstruction in the trabecular meshwork, the juxtacanalicular trabecular meshwork, or in Schlemm's canal prevents the aqueous humor from readily escaping from the anterior eye chamber, resulting in an elevation of intraocular pressure within the eye.
- the eye has a drainage system for the draining aqueous humor.
- the aqueous humor flows from a posterior chamber behind the lens 2110 through the pupil into the anterior chamber 2135 to the trabecular meshwork 2140 and into Schlemm's canal 2150 to collector channels and then to aqueous veins.
- the obstruction of the aqueous humor outflow which occurs in most open angle glaucoma typically is localized to the region of the juxtacanalicular trabecular meshwork located between the trabecular meshwork 2140 and Schlemm's canal 2150 , more specifically, the inner wall of Schlemm's canal.
- intraocular pressure gradually increases over time, leading to damage and atrophy of the optic nerve, subsequent visual field disturbances, and eventual blindness if left untreated.
- An excimer laser trabeculostomy (ELT) procedure is used to treat glaucoma.
- a delivery tip of a fiber probe 2160 is guided through a small incision, typically about 1 ⁇ 8 inch or smaller, in the cornea 2125 of the eye and across the anterior chamber 2135 to a position transverse to the Schlemm's canal 2150 .
- the fiber probe is coupled to an excimer laser source and transmits laser energy from the laser source to the trabecular meshwork 2140 and Schlemm's canal 2150 , resulting in photoablation of tissue including at least the trabecular meshwork 2140 and, in some instances, the Schlemm's canal 2150 .
- the photoablation from the laser energy creates perforations in the meshwork and/or Schlemm's canal, thereby improving fluid drainage into the Schlemm's canal 2150 and reducing intraocular pressure in the eye.
- FIG. 4 shows the arrangement of the delivery tip 2160 at a position transverse 2170 to the Schlemm's canal 2150 .
- Arrangement of the fiber probe at a transverse position to the Schlemm's canal allows the laser path to travel crosswise through the trabecular meshwork to the Schlemm's canal.
- the laser is able to provide photoablation to a greater amount of surface area of the trabecular meshwork in comparison to a fiber probe arranged at positions perpendicular or parallel to the Schlemm's canal.
- the delivery tip of the fiber probe was positioned parallel to the Schlemm's canal, the laser would not provide photoablation to any surface area of the trabecular meshwork or Schlemm's canal.
- FIG. 5 diagrams a schematic of system 200 according to certain embodiments of the invention.
- the system 200 includes an ELT instrument 201 communicatively coupled to a computer 205 .
- the system 200 optionally includes a server 209 and storage 213 . Any of the ELT instrument 201 , the computer 205 , the server 209 , and the storage 213 that are included preferably exchange data via communication network 217 .
- steps of methods of the invention may be performed using the server, which includes one or more of processors and memory, capable of obtaining data, instructions, etc., or providing results via an interface module or providing results as a file.
- the server may be provided by a single or multiple computer devices, such as the rack-mounted computers sold under the trademark BLADE by Hitachi.
- each computer preferably includes at least one processor coupled to a memory and at least one input/output (I/O) mechanism.
- a processor generally includes a chip, such as a single core or multi-core chip, to provide a central processing unit (CPU).
- a processor may be provided by a chip from Intel or AMD.
- Memory can include one or more machine-readable devices on which is stored one or more sets of instructions (e.g., software) which, when executed by the processor(s) of any one of the disclosed computers can accomplish some or all of the methodologies or functions described herein.
- a computer of the invention will generally include one or more I/O device such as, for example, one or more of a video display unit (e.g., a liquid crystal display (LCD) or a cathode ray tube (CRT)), an alphanumeric input device (e.g., a keyboard), a cursor control device (e.g., a mouse), a disk drive unit, a signal generation device (e.g., a speaker), a touchscreen, an accelerometer, a microphone, a cellular radio frequency antenna, and a network interface device, which can be, for example, a network interface card (NIC), Wi-Fi card, or cellular modem.
- a video display unit e.g., a liquid crystal display (LCD) or a cathode ray tube (CRT)
- an alphanumeric input device e.g., a keyboard
- a cursor control device e.g., a mouse
- a disk drive unit e.g., a disk
- FIG. 6 shows an embodiment of the excimer laser trabeculostomy (ELT) instrument 400 .
- An excimer laser is contained in the housing 490 .
- the housing has wheels 470 and is portable.
- the push-pull handle 455 assists with portability of the ELT instrument 400 .
- a foot pedal 480 extends from the housing 490 and is operable to provide power for delivering shots from the laser through the fiber probe 440 .
- the connector 430 of the fiber probe 440 connects to the excimer laser in the housing 490 at the fiber connection port 435 .
- the housing comprises an interactive user interface 410 .
- the interactive user interface 410 displays patient information, machine settings, and procedure information.
- the housing 490 includes control buttons, switches, and dials, such as a holder for a fiber probe cap 450 , an emergency stop button 460 , and a power switch 465 .
- FIG. 7 shows a capped version of the fiber probe 500 .
- FIG. 8 shows an uncapped version of the ELT probe or fiber probe 600 .
- the fiber probe 500 , 600 comprises an optical fiber 630 that runs through the fiber probe 600 and connects the fiber probe 600 to the excimer laser.
- the connector 610 comprises the optical fiber 630 surrounded by a protective sheath 620 .
- the connector 610 is about 200 cm to about 300 cm in length.
- a proximal end of the connector has a connection plug 605 that is operable to interact with the connection point on the instrument.
- the connection plug 605 has threads that match up with threads on the connection port to secure the connector 610 to the instrument.
- connection plug 605 has a ridge around the plug that matches up with a slot in the connection port to secure the connector 610 to the instrument.
- the connector 610 connects a connection point on the instrument (such as connection port 435 shown in FIG. 6 ) to the body 650 of the handheld fiber probe 600 .
- the fiber probe 600 is sterilized by any suitable method that provides sterilized equipment suitable for use on humans. In some embodiments, the fiber probe 600 is disposable.
- the fiber probe 600 has a tag that determines operability.
- a radio frequency identification (RFID) tag must match an RFID on the instrument in order to operate.
- the body 650 of the handheld probe is plastic.
- the body 650 of the fiber probe 500 , 600 is about 5 cm to about 10 cm in length.
- the body 650 of the fiber probe is about 7 cm in length.
- the body may have a finger grip 640 with ridges 645 .
- the fiber tip or delivery tip 660 at the distal end of the fiber probe comprises an optical fiber 630 jacketed in metal 670 , such as stainless steel or titanium.
- the delivery tip, or jacketed fiber at the distal end of the probe is inserted into the eye and guided to the trabecular meshwork.
- a foot pedal is depressed to power the excimer laser.
- a shot of energy is delivered from the excimer laser that travels through the optical fiber to the trabecular meshwork and Schlemm's canal to create a plurality of perforations in the trabecular meshwork and/or Schlemm's canal.
- FIG. 9 shows a cross-sectional view of the fiber probe across line A-A of FIG. 8 .
- the cross-section shown in A-A is the cross-section of the connector 610 from FIG. 8 .
- a protective sheath 620 surrounds the optical fiber 630 .
- the protective sheath is a protective plastic or rubber sheath.
- FIG. 10 shows a cross-sectional view of the fiber probe across line B-B of FIG. 8 .
- the cross-section shown in B-B is the cross-section of the delivery tip 660 from FIG. 8 .
- a metal jacket 670 covers the optical fiber 630 . In some cases, stainless steel is used to jacket the optical fiber in the delivery tip.
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Optics & Photonics (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Laser Surgery Devices (AREA)
Abstract
Description
- This application in a continuation patent application of U.S. application Ser. No. 16/389,460, filed Apr. 19, 2019, which is incorporated herein by reference in its entirety.
- The invention relates generally to excimer laser trabeculostomy (ELT) procedures and fiber probe placement during the procedure.
- A leading cause of irreversible blindness is glaucoma. Typically, fluid flows freely through the anterior chamber of the eye and exits through a drainage system that includes the trabecular meshwork and Schlemm's canal. When an individual suffers from glaucoma, a blockage in the trabecular meshwork or Schlemm's canal prevents the fluid from draining and results in increased pressure in the eye. If left untreated, the increased pressure in the eye damages the optic nerve, leading to gradual vision loss and eventual blindness.
- Traditional methods of treating glaucoma include pharmaceutical treatments, laser treatments, surgical treatments, or combinations thereof to lower pressure in the eye. Pharmaceutical treatments, such as medicated drops, and laser treatments, such as selective laser trabeculoplasty (SLT), often are not effective in treating advanced stages of glaucoma. Invasive surgical treatments, such as placement of implants or drainage stents, are used to treat advanced stages of glaucoma. However, the invasive surgical treatments have drawbacks and require great precision to avoid dislodgement of the implant. For example, if a stent is not placed properly on the first attempt, the stent may be difficult to place at all.
- The invention provides treatment of glaucoma using excimer laser trabeculostomy (ELT). During the ELT procedure, a laser probe is positioned transverse to the Schlemm's canal to create perforations the trabecular meshwork and/or Schlemm's canal. By permanently perforating Schlemm's canal and/or the trabecular meshwork, built-up fluid in the anterior chamber of the eye is immediately allowed to drain. Arrangement of the laser probe at a position transverse to Schlemm's canal provides optimum results by providing a greater amount of surface area for photoablation by the laser. By applying the laser at a position transverse to Schlemm's canal, each laser shot provides photoablation of a greater amount of surface area, resulting in a greater perforation from fewer laser shots.
- In open-angle glaucoma (OAG), the obstruction of fluid outflow at the trabecular meshwork and inner wall of Schlemm's canal is the primary cause of elevated intraocular pressure (TOP). The invention uses an excimer laser to perforate the trabecular meshwork and/or Schlemm's canal to create an internal outflow channel, increasing drainage of the fluid known as aqueous humor from the anterior chamber of the eye. The perforations also increase flow of aqueous humor and reduce pressure in the eye.
- Methods of the invention use ELT to reestablish outflow of fluid from the anterior chamber of the eye without inciting a healing response at the target tissue. ELT converts trabecular meshwork tissue into gas by photoablation. Ablation with excimer lasers causes almost no thermal damage, thereby minimizing inflammation and formation of scar tissue. Unlike argon and selective laser trabeculoplasty procedures, ELT precisely excises tissue without causing thermal injury or scarring the surrounding tissue. Moreover, other lasers, such as ruby and argon lasers, cannot achieve a permanent perforation of the trabecular meshwork because of inflammatory and healing responses. Due to the lack of inflammation and scar tissue formation, methods of the invention require less recovery time than traditional laser treatments or surgical treatments, such as placement of implants.
- During the ELT procedure, a physician guides a delivery tip of a fiber probe through a corneal incision in the eye and towards the trabecular meshwork. In some embodiments, methods of the invention comprise administering anesthesia to the subject before making the incision and inserting the probe. Typically, the incision has a length of about ⅛ inch or smaller. The delivery tip is guided by the physician to a position transverse to the Schlemm's canal. In some embodiments of the invention, the physician uses a light source such as a Gonio lens, endoscope, or other illumination source to aid in positioning the delivery tip. Furthermore, the light source aids the physician in verifying the effectiveness of the laser treatment by visualizing drainage of the aqueous humor and bloody reflux emitted during the treatment.
- Once the delivery tip is at a position transverse to the Schlemm's canal, the physician delivers a series of shots of laser energy to the trabecular meshwork. By providing a laser probe at a position transverse to the Schlemm's canal, or crosswise to the Schlemm's canal, energy from the laser is delivered to a greater amount of surface area than if the fiber probe was placed in a parallel or perpendicular position to the Schlemm's canal. Thus, arrangement of the delivery tip at a position transverse to the Schlemm's canal achieves optimal photoablation and perforation formation in the meshwork and/or Schlemm's canal. The creation of a plurality of perforations in leads to immediate drainage of aqueous humor from the anterior chamber of the eye.
- ELT treatment creates long-term openings that connect the anterior chamber of the eye directly to Schlemm's canal using an excimer laser. Some embodiments of the invention use a 308-nm xenon-chloride ultraviolet excimer laser, which causes minimal thermal damage compared with visible or infrared lasers. In some embodiments of the invention, the excimer laser is an encapsulated xenon chloride (XeCl) excimer laser such as the EX TRA LASER manufactured by MLase AG. Moreover, to avoid the corneal absorption of laser radiation, an optical fiber is used to deliver the energy from the excimer laser. The delivery tip of the fiber probe comprises the optical fiber jacketed in metal, such as stainless steel. In some examples of the invention, the delivery tip is beveled (e.g., at 0°, 15°, 30°, and 45° with respect to the tip). The fiber probe comprises an optical fiber suitable for UV light that is embedded into a handheld laser applicator. For example, a FIDO LASER APPLICATOR manufactured by MLase AG may be used as the fiber probe.
- To achieve easier drainage of the aqueous humor in order to reduce IOP, a total of about 10 ELT perforations, each having a diameter of about 200 μm, are lasered into the trabecular meshwork and/or Schlemm's canal. In comparison, stents and implants have smaller individual diameters that are between about 80 μm to about 120 μm. In some embodiments, about 10 shots from an excimer laser source are applied to each eye. In some embodiments, greater than about 10 shots are applied to each eye. Because ELT is a non-thermal procedure, tissue reactions in the trabecular meshwork are not shown or activated post-operatively. The lack of heat generation in ELT allows for a nearly absent activation of postoperative tissue reactions and provides long-term stability of the pressure-reducing effects. Moreover, unlike the traditional glaucoma treatment method of shunt or stent placement, the stability of Schlemm's canal using ELT treatment remains unchanged.
-
FIG. 1 is a flowchart of an embodiment of methods of the invention. -
FIG. 2 is a schematic sectional view of an embodiment of the invention in an eye. -
FIG. 3 shows the schematic section view of an eye with a light source aid. -
FIG. 4 is an enlarged schematic sectional view of an embodiment of the invention. -
FIG. 5 shows an embodiment of systems of the invention. -
FIG. 6 shows an embodiment of an ELT system. -
FIG. 7 shows a capped embodiment of a fiber probe. -
FIG. 8 shows an embodiment of a fiber probe. -
FIG. 9 shows a cross-sectional view of a fiber probe along line A-A ofFIG. 8 . -
FIG. 10 shows a cross-sectional view of a fiber probe along line B-B ofFIG. 8 . - Glaucoma patients suffer from increased intraocular pressure due to a blockage of fluid outflow from the eye. The invention uses an excimer laser to shoot perforations in the Schlemm's canal and/or trabecular meshwork of the eye. ELT treats open-angle glaucoma at the site of occurrence by increasing the permeability of the trabecular meshwork. During ELT, the laser creates a direct connection between the front chamber of the eye and the Schlemm's canal by using a fiber probe in physical contact with the trabecular meshwork.
- Methods of the invention include inserting a probe into an eye of a subject having glaucoma, adjusting placement of the probe to a position transverse to Schlemm's canal in the eye, and applying a plurality of shots from an excimer laser source while the probe is in the transverse position, thereby treating glaucoma by creating a plurality of perforations in Schlemm's canal and/or the trabecular meshwork. By providing a laser probe at a position transverse to Schlemm's canal, energy from the laser is delivered to a greater amount of surface area than if the laser was arranged in a parallel or perpendicular position to Schlemm's canal, resulting in optimal formation or perforations. The perforations allow immediate drainage of fluid from the anterior chamber of the eye. The perforations also allow for increased flow of aqueous humor in the eye and reduced intraocular pressure.
-
FIG. 1 shows a flowchart of anembodiment 100 of methods of the invention. Methods of the invention are directed to treating a patient having glaucoma with ELT. In the invention, energy shots from the excimer laser are delivered by a fiber probe at a position transverse to the Schlemm's canal. In some examples, methods include 110 pre-operative analysis, such as diagnosis of the eye condition and inspection and/or visualization of the anterior chamber of the eye to aid in placement of the laser probe. In the invention, excimer laser trabeculostomy (ELT) is used to treat glaucoma. - In some embodiments, the method includes 120 administering anesthesia to the patient. Topical anesthesia is commonly employed, typically by the instillation of a local anesthetic such as tetracaine or lidocaine. Lidocaine and/or a longer-acting bupivacaine anesthetic may be injected into the area surrounding (peribulbar block) or behind (retrobulbar block) the eye muscle cone to more fully immobilize the extraocular muscles and minimize pain sensation. Optionally, a facial nerve block may be performed using lidocaine and bupivacaine to reduce lid squeezing. In some cases, such as for children, patients with traumatic eye injuries, and nervous or uncooperative patients and animals, general anesthesia is administered with cardiovascular monitoring. To prepare the area for surgery, proper sterile precautions must be taken, including use of antiseptics like povidone-iodine and employment of sterile drapes, gowns, and gloves. are employed. In some cases, an eye speculum is inserted to keep the eyelids open.
- A
physician 130 makes a small incision on the eye of the patient. Before the ELT procedure is performed, a small incision is made in the cornea of the eye to allow introduction of the fiber probe. Typically, the incision is about ⅛ inch or smaller. - During the excimer laser trabeculostomy procedure, a physician guides the delivery tip of the fiber probe through the corneal incision in the eye and towards the trabecular meshwork. The delivery tip is 140 guided by the physician to a position transverse to the Schlemm's canal. A Gonio lens, endoscope, and/or illumination source may be used by the physician to aid in positioning the delivery tip. By providing a laser probe at a position transverse to the Schlemm's canal, or crosswise to the Schlemm's canal, the energy from the excimer laser is delivered to a greater amount of surface area than if the laser was in a parallel or perpendicular position to the Schlemm's canal. Thus, arrangement of the delivery tip at a position transverse to the Schlemm's canal achieves optimal photoablation and formation of perforations in the meshwork and/or Schlemm's canal. The orientation and positioning of the delivery tip is critical when creating perforations in the tissue, as achieving transverse placement of perforations in the meshwork relative to Schlemm's canal provides optimal drainage.
- Once the delivery tip is at a position transverse to the Schlemm's canal, the
physician 150 applies ELT treatment to the patient by delivering a series of shots of laser energy to the trabecular meshwork and Schlemm's canal. The physician applies pulsed photoablative energy. In some examples, a physician creates about 10 ELT sites in an eye of the patient. In some examples, the physician creates greater than about 10 ELT sites per eye of the patient. A small amount of bloody reflux from Schlemm's canal confirms each opening. The fiber probe is removed from the eye. The IOP decreases immediately after administering the ELT procedure. - After applying ELT treatment, a
physician 160 closes the incision. Typically, a physician uses sutures to close the incision. Some physicians place a suture in the incision and other physicians reserve a suture for instances involving persistent leakage. - Methods of the invention include 170 analyzing post-operative results and 180 reporting results and/or scheduling a post-operative follow-up appointment with the patient after surgery. For example, the physician's analysis may include observing a small amount of bloody reflux from Schlemm's canal to confirm each opening. By observing the bloody reflux and drainage of aqueous humor, the physician is able to immediately verify the effectiveness of the laser treatment. In turn, the physician may report the results to the patient, prescribe post-operative medication, such as topical antibiotics and steroid drops, and schedule any follow-up post-operative visits with the patient. Topical antibiotics and steroid drops are typically prescribed and used by the patient for 1 to 2 weeks post-operatively.
-
FIG. 2 is schematic sectional view of aneye 2100 illustrating the interior anatomical structure.FIG. 3 shows the schematic section view of aneye 2100 with alight source 2190, such as a Gonio lens, endoscope, or other light source.FIG. 4 is an enlarged schematic sectional view of the eye. The outer layer, or sclera, 2130 serves as a supporting framework for the eye, and the front of theouter layer 2130 includes acornea 2125, a transparent tissue that enables light to enter the eye. Ananterior chamber 2135 is located between thecornea 2125 and acrystalline lens 2110, and a posterior chamber is located behind thelens 2110. Theanterior chamber 2135 contains a constantly flowing clear fluid called aqueous humor. In theanterior chamber 2135, aniris 2120 encircles the outer perimeter of thelens 2110 and includes a pupil at its center, which controls the amount of light passing through thelens 2110. - The eye further includes a
trabecular meshwork 2140, which is a narrow band of spongy tissue that encircles theiris 2120 within the eye. The trabecular meshwork has a variable shape and is microscopic in size. It is of a triangular cross-section and of varying thickness in the range of about 100 microns to about 200 microns. It is made up of different fibrous layers having micron-sized pores forming fluid pathways for the egress of aqueous humor. Thetrabecular meshwork 2140 has been measured to a thickness of about 100 microns at its anterior edge, known as Schwalbe's line, which is at the approximate juncture of the cornea and sclera. - The trabecular meshwork widens to about 200 microns at its base where it and
iris 2120 attach to the scleral spur. The passageways through the pores intrabecular meshwork 2140 lead through very thin, porous tissue called the juxtacanalicular trabecular meshwork that abuts the interior side of a structure called Schlemm'scanal 2150. Schlemm'scanal 2150 is filled with a mixture of aqueous humor and blood components and branches off into collector channels which drain the aqueous humor into the venous system. Because aqueous humor is constantly produced by the eye, any obstruction in the trabecular meshwork, the juxtacanalicular trabecular meshwork, or in Schlemm's canal prevents the aqueous humor from readily escaping from the anterior eye chamber, resulting in an elevation of intraocular pressure within the eye. - The eye has a drainage system for the draining aqueous humor. The aqueous humor flows from a posterior chamber behind the
lens 2110 through the pupil into theanterior chamber 2135 to thetrabecular meshwork 2140 and into Schlemm'scanal 2150 to collector channels and then to aqueous veins. The obstruction of the aqueous humor outflow which occurs in most open angle glaucoma (i.e., glaucoma characterized by gonioscopically readily visible trabecular meshwork) typically is localized to the region of the juxtacanalicular trabecular meshwork located between thetrabecular meshwork 2140 and Schlemm'scanal 2150, more specifically, the inner wall of Schlemm's canal. When an obstruction develops, such as at the juxtacanalicular trabecular meshwork or at Schlemm's canal, intraocular pressure gradually increases over time, leading to damage and atrophy of the optic nerve, subsequent visual field disturbances, and eventual blindness if left untreated. - An excimer laser trabeculostomy (ELT) procedure according to the invention is used to treat glaucoma. A delivery tip of a
fiber probe 2160 is guided through a small incision, typically about ⅛ inch or smaller, in thecornea 2125 of the eye and across theanterior chamber 2135 to a position transverse to the Schlemm'scanal 2150. The fiber probe is coupled to an excimer laser source and transmits laser energy from the laser source to thetrabecular meshwork 2140 and Schlemm'scanal 2150, resulting in photoablation of tissue including at least thetrabecular meshwork 2140 and, in some instances, the Schlemm'scanal 2150. The photoablation from the laser energy creates perforations in the meshwork and/or Schlemm's canal, thereby improving fluid drainage into the Schlemm'scanal 2150 and reducing intraocular pressure in the eye. -
FIG. 4 shows the arrangement of thedelivery tip 2160 at a position transverse 2170 to the Schlemm'scanal 2150. Arrangement of the fiber probe at a transverse position to the Schlemm's canal allows the laser path to travel crosswise through the trabecular meshwork to the Schlemm's canal. By positioning the fiber probe transverse to the Schlemm's canal, the laser is able to provide photoablation to a greater amount of surface area of the trabecular meshwork in comparison to a fiber probe arranged at positions perpendicular or parallel to the Schlemm's canal. Moreover, if the delivery tip of the fiber probe was positioned parallel to the Schlemm's canal, the laser would not provide photoablation to any surface area of the trabecular meshwork or Schlemm's canal. -
FIG. 5 diagrams a schematic ofsystem 200 according to certain embodiments of the invention. Thesystem 200 includes anELT instrument 201 communicatively coupled to acomputer 205. Thesystem 200 optionally includes aserver 209 andstorage 213. Any of theELT instrument 201, thecomputer 205, theserver 209, and thestorage 213 that are included preferably exchange data viacommunication network 217. Where methods of the invention employ a client/server architecture, steps of methods of the invention may be performed using the server, which includes one or more of processors and memory, capable of obtaining data, instructions, etc., or providing results via an interface module or providing results as a file. The server may be provided by a single or multiple computer devices, such as the rack-mounted computers sold under the trademark BLADE by Hitachi. Insystem 200, each computer preferably includes at least one processor coupled to a memory and at least one input/output (I/O) mechanism. - A processor generally includes a chip, such as a single core or multi-core chip, to provide a central processing unit (CPU). A processor may be provided by a chip from Intel or AMD. Memory can include one or more machine-readable devices on which is stored one or more sets of instructions (e.g., software) which, when executed by the processor(s) of any one of the disclosed computers can accomplish some or all of the methodologies or functions described herein. A computer of the invention will generally include one or more I/O device such as, for example, one or more of a video display unit (e.g., a liquid crystal display (LCD) or a cathode ray tube (CRT)), an alphanumeric input device (e.g., a keyboard), a cursor control device (e.g., a mouse), a disk drive unit, a signal generation device (e.g., a speaker), a touchscreen, an accelerometer, a microphone, a cellular radio frequency antenna, and a network interface device, which can be, for example, a network interface card (NIC), Wi-Fi card, or cellular modem. The
system 200 may be used to perform methods described herein. Instructions for any method step may be stored in memory and a processor may execute those instructions. -
FIG. 6 shows an embodiment of the excimer laser trabeculostomy (ELT)instrument 400. An excimer laser is contained in thehousing 490. The housing haswheels 470 and is portable. The push-pull handle 455 assists with portability of theELT instrument 400. Afoot pedal 480 extends from thehousing 490 and is operable to provide power for delivering shots from the laser through thefiber probe 440. Theconnector 430 of thefiber probe 440 connects to the excimer laser in thehousing 490 at thefiber connection port 435. The housing comprises aninteractive user interface 410. In some examples, theinteractive user interface 410 displays patient information, machine settings, and procedure information. Thehousing 490 includes control buttons, switches, and dials, such as a holder for afiber probe cap 450, anemergency stop button 460, and apower switch 465. -
FIG. 7 shows a capped version of thefiber probe 500.FIG. 8 shows an uncapped version of the ELT probe orfiber probe 600. Thefiber probe optical fiber 630 that runs through thefiber probe 600 and connects thefiber probe 600 to the excimer laser. Theconnector 610 comprises theoptical fiber 630 surrounded by aprotective sheath 620. In an example of the invention, theconnector 610 is about 200 cm to about 300 cm in length. A proximal end of the connector has aconnection plug 605 that is operable to interact with the connection point on the instrument. In an example, theconnection plug 605 has threads that match up with threads on the connection port to secure theconnector 610 to the instrument. In an example, theconnection plug 605 has a ridge around the plug that matches up with a slot in the connection port to secure theconnector 610 to the instrument. Theconnector 610 connects a connection point on the instrument (such asconnection port 435 shown inFIG. 6 ) to thebody 650 of thehandheld fiber probe 600. - The
fiber probe 600 is sterilized by any suitable method that provides sterilized equipment suitable for use on humans. In some embodiments, thefiber probe 600 is disposable. - In some embodiments, the
fiber probe 600 has a tag that determines operability. In some examples, a radio frequency identification (RFID) tag must match an RFID on the instrument in order to operate. In an embodiment, thebody 650 of the handheld probe is plastic. In an embodiment, thebody 650 of thefiber probe body 650 of the fiber probe is about 7 cm in length. Optionally, the body may have afinger grip 640 withridges 645. The fiber tip ordelivery tip 660 at the distal end of the fiber probe comprises anoptical fiber 630 jacketed inmetal 670, such as stainless steel or titanium. The delivery tip, or jacketed fiber at the distal end of the probe, is inserted into the eye and guided to the trabecular meshwork. A foot pedal is depressed to power the excimer laser. When powered, a shot of energy is delivered from the excimer laser that travels through the optical fiber to the trabecular meshwork and Schlemm's canal to create a plurality of perforations in the trabecular meshwork and/or Schlemm's canal. -
FIG. 9 shows a cross-sectional view of the fiber probe across line A-A ofFIG. 8 . The cross-section shown in A-A is the cross-section of theconnector 610 fromFIG. 8 . Aprotective sheath 620 surrounds theoptical fiber 630. In some examples, the protective sheath is a protective plastic or rubber sheath.FIG. 10 shows a cross-sectional view of the fiber probe across line B-B ofFIG. 8 . The cross-section shown in B-B is the cross-section of thedelivery tip 660 fromFIG. 8 . Ametal jacket 670 covers theoptical fiber 630. In some cases, stainless steel is used to jacket the optical fiber in the delivery tip. - References and citations to other documents, such as patents, patent applications, patent publications, journals, books, papers, and web contents made throughout this disclosure are hereby incorporated herein by reference in their entirety for all purposes.
- While the present invention has been described in conjunction with certain embodiments, one of ordinary skill, after reading the foregoing specification, will be able to effect various changes, substitutions of equivalents, and other alterations to the compositions and methods set forth herein.
Claims (23)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/363,726 US20220023098A1 (en) | 2019-04-19 | 2021-06-30 | Methods of transverse placement in elt |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/389,460 US11076992B2 (en) | 2019-04-19 | 2019-04-19 | Methods of transverse placement in ELT |
US17/363,726 US20220023098A1 (en) | 2019-04-19 | 2021-06-30 | Methods of transverse placement in elt |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/389,460 Continuation US11076992B2 (en) | 2019-04-19 | 2019-04-19 | Methods of transverse placement in ELT |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220023098A1 true US20220023098A1 (en) | 2022-01-27 |
Family
ID=72833442
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/389,460 Active 2039-08-15 US11076992B2 (en) | 2019-04-19 | 2019-04-19 | Methods of transverse placement in ELT |
US17/363,726 Abandoned US20220023098A1 (en) | 2019-04-19 | 2021-06-30 | Methods of transverse placement in elt |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/389,460 Active 2039-08-15 US11076992B2 (en) | 2019-04-19 | 2019-04-19 | Methods of transverse placement in ELT |
Country Status (6)
Country | Link |
---|---|
US (2) | US11076992B2 (en) |
EP (1) | EP3955868A4 (en) |
CN (1) | CN114206276A (en) |
AU (1) | AU2020257291B2 (en) |
CA (1) | CA3137170A1 (en) |
WO (1) | WO2020215069A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220151828A1 (en) * | 2019-04-19 | 2022-05-19 | Elios Vision, Inc. | Combination treatment using elt |
US11529260B2 (en) | 2019-04-19 | 2022-12-20 | Elios Vision, Inc. | Systems and methods for performing an intraocular procedure for treating an eye condition |
US11633234B2 (en) | 2019-04-19 | 2023-04-25 | Elios Vision, Inc. | Enhanced fiber probes for ELT |
US11666482B2 (en) | 2019-04-19 | 2023-06-06 | Elios Vision, Inc. | Personalization of excimer laser fibers |
US11877951B1 (en) | 2022-08-30 | 2024-01-23 | Elios Vision, Inc. | Systems and methods for applying excimer laser energy with transverse placement in the eye |
US11903876B1 (en) | 2022-08-30 | 2024-02-20 | Elios Vision, Inc. | Systems and methods for prophylactic treatment of an eye using an excimer laser unit |
US11918516B1 (en) | 2022-08-30 | 2024-03-05 | Elios Vision, Inc. | Systems and methods for treating patients with closed-angle or narrow-angle glaucoma using an excimer laser unit |
US11974890B2 (en) | 2019-04-19 | 2024-05-07 | Elios Vision Inc. | Authentication systems and methods for an excimer laser system |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220038361A (en) | 2019-07-01 | 2022-03-28 | 마이클 에스. 베를린 | Image guidance method and device for glaucoma surgery |
KR20230005198A (en) | 2020-04-02 | 2023-01-09 | 메드 프로그레스, 엘엘씨 | Reduction or inhibition of ocular damage by hyaluronidase administration |
US11890331B2 (en) * | 2020-04-02 | 2024-02-06 | Med Progress, LLC | Reducing or inhibiting ocular damage by hyaluronidase administration |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150080783A1 (en) * | 2000-05-19 | 2015-03-19 | Michael S. Berlin | Delivery System and Method of Use for the Eye |
US20190254746A1 (en) * | 2018-02-20 | 2019-08-22 | The Spectranetics Corporation | Optical assembly for laser generator |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4607622A (en) | 1985-04-11 | 1986-08-26 | Charles D. Fritch | Fiber optic ocular endoscope |
ATE155024T1 (en) | 1991-05-06 | 1997-07-15 | Martin M D Uram | LASER VIDEO ENDOSCOPE |
ATE211008T1 (en) | 1992-04-10 | 2002-01-15 | Surgilight Inc | DEVICE FOR PERFORMING EYE SURGERY |
US6283974B1 (en) | 1997-11-14 | 2001-09-04 | Aaron James Alexander | Surgical tip for phacoemulsification |
DE19920615A1 (en) | 1999-05-05 | 2000-12-07 | Tui Laser Ag | Device for treating glaucorn of the eye |
DE10023176A1 (en) | 2000-05-11 | 2001-11-15 | Glautec Ag | Glaucoma treatment device |
US8679089B2 (en) * | 2001-05-21 | 2014-03-25 | Michael S. Berlin | Glaucoma surgery methods and systems |
ATE377404T1 (en) | 2000-05-19 | 2007-11-15 | Michael S Berlin | LASER APPLICATION SYSTEM AND METHOD FOR USE IN THE EYE |
US6743221B1 (en) | 2001-03-13 | 2004-06-01 | James L. Hobart | Laser system and method for treatment of biological tissues |
DE10138984A1 (en) * | 2001-08-08 | 2003-03-06 | Glautec Ag | Appliance for treatment of glaucoma controls treatment beam based on measurement beam reflected light from Schlems canal |
US7582057B2 (en) | 2004-02-24 | 2009-09-01 | Japan Atomic Energy Research Institute | Endoscopic system using an extremely fine composite optical fiber |
US7331954B2 (en) | 2004-04-08 | 2008-02-19 | Omniguide, Inc. | Photonic crystal fibers and medical systems including photonic crystal fibers |
US7568619B2 (en) | 2004-12-15 | 2009-08-04 | Alcon, Inc. | System and method for identifying and controlling ophthalmic surgical devices and components |
AU2006238845B2 (en) * | 2005-04-22 | 2010-04-08 | Biolase, Inc. | Methods for treating hyperopia and presbyopia via laser tunneling |
US7837694B2 (en) | 2005-04-28 | 2010-11-23 | Warsaw Orthopedic, Inc. | Method and apparatus for surgical instrument identification |
WO2006125280A1 (en) | 2005-05-27 | 2006-11-30 | Opto Global Holdings Pty Ltd | System and method for laser calibration |
WO2006135701A2 (en) | 2005-06-10 | 2006-12-21 | Omniguide, Inc. | Photonic crystal fibres and endoscope using such a fibre |
US8876810B2 (en) | 2006-03-20 | 2014-11-04 | Biolitec Pharma Marketing Ltd | Benign prostatic hyperplasia treatment method and device |
US10098781B2 (en) | 2006-03-24 | 2018-10-16 | Topcon Medical Laser Systems Inc. | Multi-spot optical fiber endophotocoagulation probe |
CN101113953B (en) * | 2006-07-28 | 2010-05-26 | 清华大学 | Method for manufacturing optical fiber detecting probe |
DE102007049239A1 (en) | 2006-10-20 | 2008-04-24 | Carl Zeiss Meditec Ag | Endo probe for microsurgery i.e. eye surgery, has optical fibers, into which laser light is directly injected, and casing, where coupling of illuminating light is provided in casing or transparent form element over optical element |
US20080108979A1 (en) | 2006-11-03 | 2008-05-08 | William Telfair | Flush Tip Illuminating Laser Probe Treatment Apparatus |
US20080108983A1 (en) | 2006-11-07 | 2008-05-08 | Synergetics, Inc. | Dual Core Optic Fiber Illuminated Laser Probe |
US20090157064A1 (en) | 2007-05-11 | 2009-06-18 | Hodel Michael R | RFID System and Method Therefor |
US20100324543A1 (en) | 2007-09-18 | 2010-12-23 | Kurtz Ronald M | Method And Apparatus For Integrating Cataract Surgery With Glaucoma Or Astigmatism Surgery |
US8647333B2 (en) | 2007-11-03 | 2014-02-11 | Cygnus Llc | Ophthalmic surgical device |
US10080684B2 (en) | 2008-03-13 | 2018-09-25 | Optimedica Corporation | System and method for laser corneal incisions for keratoplasty procedures |
WO2012135073A2 (en) | 2011-03-25 | 2012-10-04 | Board Of Trustees Of Michigan State University | Adaptive laser system for ophthalmic use |
US20130041357A1 (en) | 2011-08-12 | 2013-02-14 | Ceramoptec Industries Inc. | Class 1 laser treatment system |
US11175462B2 (en) | 2011-09-09 | 2021-11-16 | Boston Scientific Scimed, Inc. | Split surgical laser fiber |
ES2683313T3 (en) * | 2011-09-29 | 2018-09-26 | Biolase, Inc. | Devices to treat eye conditions |
SI24223A (en) | 2012-10-30 | 2014-05-30 | OPTOTEK d.o.o. Tehnološki park 21 | Ophthalmia laser combined device |
CN105188589B (en) | 2013-03-15 | 2018-02-06 | 安玛莉·希思黎 | For the system for the biomechanical properties for influenceing connective tissue |
CN105764436B (en) | 2013-09-06 | 2019-04-26 | 普罗赛普特生物机器人公司 | Utilize the device for ablation tissue for causing de- pulse |
CN110338968B (en) | 2013-11-28 | 2023-05-26 | 爱尔康公司 | Ophthalmic surgical systems, methods, and devices |
JP6464165B2 (en) | 2014-06-26 | 2019-02-06 | 富士フイルム株式会社 | Photoacoustic measuring device and probe for photoacoustic measurement |
JP6941623B2 (en) | 2016-04-20 | 2021-09-29 | クーパーサージカル・インコーポレイテッドCooperSurgical, Inc. | Beam steering and related methods for laser systems |
CN109414291B (en) | 2016-06-30 | 2022-03-29 | 艾瑞黛克斯公司 | Handheld ophthalmic laser system with replaceable contact tip and treatment guide |
US20180042772A1 (en) | 2016-08-12 | 2018-02-15 | Cygnus LP | Variable-gauge microsurgical instruments for use in ophthalmic or vitreoretinal surgery |
MX2019011750A (en) | 2017-03-31 | 2020-01-23 | Hipsley Annmarie | Systems and methods for ocular laser surgery and therapeutic treatments. |
US10918522B2 (en) | 2017-06-08 | 2021-02-16 | Alcon Inc. | Photodisruption-based vitrectomy system |
US20180360655A1 (en) | 2017-06-16 | 2018-12-20 | Michael S. Berlin | Methods and systems for oct guided glaucoma surgery |
WO2019060756A1 (en) * | 2017-09-21 | 2019-03-28 | Aleyegn Technologies Llc | Angle-opening glaucoma treatment methods and apparatus |
US20200330275A1 (en) | 2019-04-19 | 2020-10-22 | Elt Sight, Inc. | Combination treatment using phaco and elt |
US11389239B2 (en) | 2019-04-19 | 2022-07-19 | Elios Vision, Inc. | Enhanced fiber probes for ELT |
US11672475B2 (en) | 2019-04-19 | 2023-06-13 | Elios Vision, Inc. | Combination treatment using ELT |
US11076933B2 (en) | 2019-04-19 | 2021-08-03 | Elt Sight, Inc. | Authentication systems and methods for an excimer laser system |
US11234866B2 (en) | 2019-04-19 | 2022-02-01 | Elios Vision, Inc. | Personalization of excimer laser fibers |
US20200330281A1 (en) | 2019-04-19 | 2020-10-22 | Elt Sight, Inc. | Excimer laser fiber illumination |
US11103382B2 (en) | 2019-04-19 | 2021-08-31 | Elt Sight, Inc. | Systems and methods for preforming an intraocular procedure for treating an eye condition |
-
2019
- 2019-04-19 US US16/389,460 patent/US11076992B2/en active Active
-
2020
- 2020-04-20 CN CN202080040949.8A patent/CN114206276A/en active Pending
- 2020-04-20 EP EP20792132.1A patent/EP3955868A4/en active Pending
- 2020-04-20 WO PCT/US2020/028971 patent/WO2020215069A1/en active Application Filing
- 2020-04-20 AU AU2020257291A patent/AU2020257291B2/en active Active
- 2020-04-20 CA CA3137170A patent/CA3137170A1/en active Pending
-
2021
- 2021-06-30 US US17/363,726 patent/US20220023098A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150080783A1 (en) * | 2000-05-19 | 2015-03-19 | Michael S. Berlin | Delivery System and Method of Use for the Eye |
US20190254746A1 (en) * | 2018-02-20 | 2019-08-22 | The Spectranetics Corporation | Optical assembly for laser generator |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220151828A1 (en) * | 2019-04-19 | 2022-05-19 | Elios Vision, Inc. | Combination treatment using elt |
US11464677B2 (en) * | 2019-04-19 | 2022-10-11 | Elios Vision, Inc. | Combination treatment using ELT |
US11529260B2 (en) | 2019-04-19 | 2022-12-20 | Elios Vision, Inc. | Systems and methods for performing an intraocular procedure for treating an eye condition |
US11633234B2 (en) | 2019-04-19 | 2023-04-25 | Elios Vision, Inc. | Enhanced fiber probes for ELT |
US11666482B2 (en) | 2019-04-19 | 2023-06-06 | Elios Vision, Inc. | Personalization of excimer laser fibers |
US11672475B2 (en) | 2019-04-19 | 2023-06-13 | Elios Vision, Inc. | Combination treatment using ELT |
US11865045B2 (en) | 2019-04-19 | 2024-01-09 | Elios Vision, Inc. | Systems and methods for performing an intraocular procedure for treating an eye condition |
US11974890B2 (en) | 2019-04-19 | 2024-05-07 | Elios Vision Inc. | Authentication systems and methods for an excimer laser system |
US11992264B2 (en) | 2019-04-19 | 2024-05-28 | Elios Vision, Inc. | Enhanced fiber probes for ELT |
US11877951B1 (en) | 2022-08-30 | 2024-01-23 | Elios Vision, Inc. | Systems and methods for applying excimer laser energy with transverse placement in the eye |
US11903876B1 (en) | 2022-08-30 | 2024-02-20 | Elios Vision, Inc. | Systems and methods for prophylactic treatment of an eye using an excimer laser unit |
US11918516B1 (en) | 2022-08-30 | 2024-03-05 | Elios Vision, Inc. | Systems and methods for treating patients with closed-angle or narrow-angle glaucoma using an excimer laser unit |
Also Published As
Publication number | Publication date |
---|---|
EP3955868A1 (en) | 2022-02-23 |
AU2020257291B2 (en) | 2021-12-02 |
WO2020215069A1 (en) | 2020-10-22 |
EP3955868A4 (en) | 2023-01-11 |
CA3137170A1 (en) | 2020-10-22 |
US20200330274A1 (en) | 2020-10-22 |
CN114206276A (en) | 2022-03-18 |
US11076992B2 (en) | 2021-08-03 |
AU2020257291A1 (en) | 2021-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020257291B2 (en) | Methods of transverse placement in ELT | |
US20220387218A1 (en) | Combination treatment using phaco and elt | |
US11633234B2 (en) | Enhanced fiber probes for ELT | |
US11464677B2 (en) | Combination treatment using ELT | |
US10687978B2 (en) | Delivery system and method of use for the eye | |
EP3955873B1 (en) | Personalization of excimer laser fibers | |
US11877951B1 (en) | Systems and methods for applying excimer laser energy with transverse placement in the eye | |
US11903876B1 (en) | Systems and methods for prophylactic treatment of an eye using an excimer laser unit | |
US11918516B1 (en) | Systems and methods for treating patients with closed-angle or narrow-angle glaucoma using an excimer laser unit | |
US20240065893A1 (en) | Systems and methods for a combined excimer laser and phacoemulsification unit | |
Ali et al. | Conjunctivodacryocystorhinostomy: indications, techniques, and complications | |
WO2024050363A1 (en) | Systems and methods for prophylactic treatment of an eye using an excimer laser unit | |
Kuhn et al. | Endolaser |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ELT SIGHT, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JUNGER, JOHANNES;ENDERS, MARKUS;REEL/FRAME:057102/0035 Effective date: 20200409 |
|
AS | Assignment |
Owner name: ELIOS VISION, INC., CALIFORNIA Free format text: CHANGE OF NAME;ASSIGNOR:ELT SIGHT, INC.;REEL/FRAME:057511/0969 Effective date: 20210830 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |